5418-97-3

Usage

Uses

Used in Organic Synthesis:
(Z)-[4-(ethoxycarbonyl)phenyl](imino)methanaminium chloride is used as a building block for the synthesis of more complex organic molecules. Its unique structure, which includes a phenyl group, an ethoxycarbonyl substituent, and an imino group, allows it to participate in various chemical reactions, facilitating the creation of a wide range of compounds.
Used in Chemical Reactions:
In the chemical industry, (Z)-[4-(ethoxycarbonyl)phenyl](imino)methanaminium chloride is used as a reactant in different chemical reactions. Its reactivity, stemming from the presence of the chloride ion and the imino group, makes it suitable for use in the formation of new chemical entities, potentially leading to novel materials or pharmaceuticals.
Used in Pharmaceutical Development:
(Z)-[4-(ethoxycarbonyl)phenyl](imino)methanaminium chloride may be utilized as a starting material or intermediate in the development of new pharmaceuticals. Its structural features could be exploited to design drugs targeting specific biological receptors or enzymes, contributing to the advancement of medical treatments.
Used in Material Science:
In the field of material science, (Z)-[4-(ethoxycarbonyl)phenyl](imino)methanaminium chloride could be employed in the development of new materials with unique properties. Its chemical structure may allow for the creation of polymers or other materials with specific characteristics, such as improved strength, flexibility, or conductivity.

Upstream product

• 66631-28-5 4-carbethoxyimidobenzoesaeureethylester-hydrochloride 
• 619-65-8 4-cyanobenzoic Acid 
• 7153-22-2 ethyl 4-cyanobenzoate 

Downstream Products

• 133594-55-5 ethyl p-(5-hexylpyrimidyl)-benzoate 
• 78385-09-8 [2-(3-Chloro-phenyl)-pyrimidin-4-yl]-hydrazine 
• 97604-14-3 4-(4-chloropyrimidin-2-yl)benzic acid ethyl ester 
• 97582-70-2 5-(3-chlorophenyl)[1,2,4]triazolo[1,5-c]pyrimidin-2-amine 
• 97603-46-8 4-(4-Hydrazino-pyrimidin-2-yl)-benzoic acid ethyl ester 
• 97582-63-3 4-(2-amino [1,2,4]triazolo[1,5-c]pyrimidin-5-yl)benzoic acid, ethyl ester 
• 15535-95-2 4-(aminoiminomethyl)benzoic acid 
• 133883-30-4 4-(5-Hexyl-pyrimidin-2-yl)-benzoic acid 4-nonyl-phenyl ester 
• 133883-34-8 4-(5-Hexyl-pyrimidin-2-yl)-benzoic acid 4-hexyloxy-phenyl ester 
• 133883-33-7 4-(5-Hexyl-pyrimidin-2-yl)-benzoic acid 4-pentyloxy-phenyl ester 
• 133883-29-1 4-(5-Hexyl-pyrimidin-2-yl)-benzoic acid 4-hexyl-phenyl ester 
• 133883-37-1 4-(5-Hexyl-pyrimidin-2-yl)-benzoic acid 4-(2-cyano-ethyl)-phenyl ester 
• 129513-96-8 4-(5-Hexyl-pyrimidin-2-yl)-benzoic acid 4-pentyl-phenyl ester 
• 129249-09-8 4-(5-Hexyl-pyrimidin-2-yl)-benzoic acid 4-cyano-3-methyl-phenyl ester 

Relevant academic research and scientific papers

NOVEL ETHYLENEDIAMINE DERIVATIVES

A compound represented by the following formula (1):Q-Q-T-N(R)-Q-N(R)-T-Q [wherein, R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may have a substituent, or the like; Q2 is a single bond or the like; Q3 represents the following group: -C(R3a)(R4a)-{C(R3b)(R4b)}m1-{C(R3c)(R4c)}m2-{C(R3d)(R4d)}m3-{C(R3e)(R4e)}m4-C(R3f)(R4f)- (in which, R3a to R4e represent hydrogen or the like); T0 represents a carbonyl group or the like; and T1 represents -COCONR- or the like]; or salt thereof, solvate thereof, or N-oxide thereof. The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

NOVEL SULFONYL DERIVATIVES

Sulfonyl derivatives represented by the following general formula (I): Q1-Q2-T1-Q3-SO2-QA and drugs containing the same (wherein Q1 is an optionally substituted, saturated or unsaturated, five- or six-membered cyclic hydrocarbon group, a five- or six-membered heterocyclic group, or the like; Q2 is a single band, oxygen, sulfur, C1-C6 alkylene or the like; QA is optionally substituted arylalkenyl, heteroarylalkenyl or the like; and T1 is carbonyl or the like). These compounds have potent FXa-inhibitory effects and promptly exert satisfactory and persistent antithrombotic effects through oral administration, thus being useful as anticoagulant agents little accompanied with side effects.

Preparation of Triazolopyrimidines as Potential Antiasthma Agents

With the use of the human basophil histamine release assay, 5-aryl-2-aminotriazolopyrimidines were found to be active as mediator release inhibitors.These compounds were prepared by reacting arylamidines with sodium ethyl formylacetate or with ethyl propiolate to give pyrimidinones.Treatment with phosphorus oxychloride gave a chloropyrimidine, which was converted to a hydrazinopyrimidine with hydrazine.Cyclization, using cyanogen bromide, gave the triazolopyrimidines, after a Dimroth rearrangement.Following a structure-activity evaluation, the5--2-amino (8-10), 5-(3-bromophenyl)-2-amino (8-13), 5--2-amino (8-11), and 5-(4-pyridinyl)-2-amino (6-7) compounds were found to have the best activity.They were chosen for further pharmacological and toxicological study.